Delmosart 36mg is an extended-release (prolonged-release) formulation of Methylphenidate Hydrochloride, a central nervous system (CNS) stimulant prescribed primarily for the management of Attention Deficit Hyperactivity Disorder (ADHD). The prolonged-release technology provides gradual delivery of the medication throughout the day, helping maintain symptom control while reducing the need for multiple daily doses.
Delmosart is commonly prescribed as part of a comprehensive ADHD treatment plan that may include behavioral therapy, educational support, counseling, and lifestyle interventions. Because it contains methylphenidate, it is classified as a controlled prescription medicine and should only be used under the supervision of a qualified healthcare professional.
Delmosart 36mg contains Methylphenidate Hydrochloride, a medicine that increases the activity of dopamine and norepinephrine in the brain. These neurotransmitters play a key role in attention, concentration, impulse control, and executive functioning.
The prolonged-release formulation is designed to release the medication over several hours, providing sustained symptom control for many patients throughout the day.
Healthcare professionals may prescribe Delmosart 36mg for:
Delmosart should only be used for medically approved indications and under the guidance of a healthcare provider.
Delmosart increases the levels of dopamine and norepinephrine in certain parts of the brain responsible for attention, focus, and behavioral regulation.
The extended-release delivery system gradually releases methylphenidate throughout the day, helping maintain more consistent therapeutic effects compared with immediate-release formulations.
Medication is generally most effective when combined with behavioral interventions, educational support, and regular medical follow-up.
When prescribed appropriately, Delmosart may help:
Treatment response varies from person to person.
Delmosart may be available in several strengths, including:
Availability varies depending on the market and importer.
The correct dosage depends on factors such as:
Only your healthcare provider should determine the appropriate dose and make any adjustments.
General recommendations:
If you miss a dose, consult your healthcare provider rather than taking an extra dose.
Common side effects may include:
Less common but serious side effects include chest pain, severe allergic reactions, hallucinations, mood changes, or circulation problems in the fingers or toes. Seek immediate medical attention if these occur.
Before taking Delmosart, tell your healthcare provider if you have:
Regular monitoring of blood pressure, pulse, weight, growth (in children), and treatment response is recommended.
Delmosart may interact with:
Always provide your healthcare provider with a complete list of prescription medicines, over-the-counter medicines, vitamins, and herbal supplements you take.
If you are pregnant, planning pregnancy, or breastfeeding, discuss the potential benefits and risks of Delmosart treatment with your healthcare provider before use.
Store Delmosart tablets:
Follow the storage instructions provided on the manufacturer's packaging.
Delmosart 36mg may be available through licensed pharmacies and authorized medicine importers in Pakistan. Availability depends on stock levels and local regulations. Because it is a controlled prescription medicine, it is generally supplied only with a valid prescription.
This information is intended for educational and product-description purposes only. Delmosart 36mg is a prescription-only controlled medicine and should be used only under the supervision of a qualified healthcare professional. It is not intended to replace professional medical advice, diagnosis, or treatment.
Delmosart 36mg is primarily prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The active ingredient is Methylphenidate Hydrochloride 36mg in a prolonged-release formulation.
The estimated price ranges from PKR 7,500 to PKR 13,500, depending on the pharmacy, importer, and availability.
It may be available through selected pharmacies and licensed medicine importers, subject to local regulations and stock availability.
Yes. Delmosart contains methylphenidate and is a prescription-only controlled medicine.
It may be prescribed for children with ADHD when recommended by a qualified healthcare professional.
Yes. Adults with ADHD may be prescribed Delmosart if their healthcare provider considers it appropriate.
Common side effects include reduced appetite, insomnia, headache, dry mouth, nausea, stomach discomfort, nervousness, and increased heart rate.
Do not stop taking Delmosart without consulting your healthcare provider, as treatment changes should be supervised.
Yes. Because it contains methylphenidate, it has a potential for misuse and dependence. Use it only exactly as prescribed.
Some people may experience side effects that affect alertness. Follow your healthcare provider's advice regarding driving or operating machinery.
Store the tablets in their original packaging at room temperature, away from moisture, excessive heat, and direct sunlight, and keep them out of the reach of children.
Customers Reviews For Delmosart 36mg Price in Pakistan